Skip to main content
Premium Trial:

Request an Annual Quote

BillionToOne Raises $125M in Series C Funding Round

NEW YORK – Molecular diagnostics company BillionToOne said on Wednesday that it has closed an oversubscribed Series C funding round in which it raised $125 million.

Adam Street Partners and existing investor Hummingbird Ventures led the round, joined by Baillie Gifford, Neotribe Ventures, Norwest Venture Partners, Civilization Ventures, Fifty Years VC, Pacific 8 Ventures, Time BioVentures, and Libertus Capital, among others.

Thomas Bremner, a partner at Adams Street Partners, will also join BillionToOne's board of directors.

BillionToOne plans to use the new funding to expand its commercial and clinical teams, scale up lab capacity, and conduct clinical studies of its Unity Screen prenatal liquid biopsy test, which it launched two years ago.

The company, which previously raised $55 million in a Series B round, has also begun adapting its cell-free DNA sequencing technology for use in cancer therapy selection and response monitoring. That test is expected to launch later this year.

"Our prenatal test is solving a critical unmet medical need," Oguzhan Atay, cofounder and CEO of BillionToOne, said in a statement. "We continue to grow at an incredible rate, and we are building out an ever-increasing set of larger laboratory facilities. The current funding will be used to support our prenatal test growth while launching our differentiated liquid biopsy test that will transform oncology care."